In a landmark decision on November 18, 2026, the U.S. Food and Drug Administration (FDA) approved Infilbray (venglustat), a once-daily oral medication developed by Sanofi, as the first treatment to address neurological symptoms in patients with Type 3 Gaucher disease (GD3). The FDA’s move marks a milestone for individuals living with the rare, inherited disorder—one that for decades left a critical aspect of the disease largely untreated.
GD3 results from the buildup of fatty substances in organs and the brain, causing progressive, devastating effects on both the body and nervous system. Unlike earlier therapies, which primarily managed systemic symptoms, Infilbray is designed specifically to cross the blood-brain barrier and reduce the harmful accumulations at the root of neurological decline. The newly approved treatment is indicated for both adults and children weighing at least 15 kilograms (about 33 pounds).
A New Era for GD3 Patients
The FDA based its approval on data from a randomized, double-blind clinical trial involving 43 patients aged 12 years and older with stabilized systemic disease after previous enzyme replacement therapy. Participants received either daily oral Infilbray or continued intravenous enzyme replacement therapy for 52 weeks. At the end of the study, those receiving Infilbray showed measurable improvement in neurological functions, specifically in areas of muscle coordination (ataxia) and cognitive skills crucial to daily life.
“This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them,” said acting FDA Commissioner Kyle Diamantas, in the agency’s official statement. Prior treatments in GD3 had limited or no effect on neurological deterioration, often leaving families and patients with few options as symptoms worsened over time.
Benefits and Cautions
Side effects observed with Infilbray included gastrointestinal symptoms and impacts on mood; serious psychiatric risks, including suicidal thoughts or behaviors, were also reported and are highlighted in drug labeling. Children and pregnant patients are cautioned about potential risks involving vision and fetal development, respectively. Infilbray was granted both Orphan Drug status and a Priority Review designation due to its novel impact on a population with severe unmet needs.
Sanofi, the developer of Infilbray (marketed through its Genzyme subsidiary), plans to seek further regulatory approvals in Europe, Japan, and other regions in the coming year. Details regarding pricing, insurance coverage, and U.S. distribution are yet to be announced.
The approval establishes a new path for addressing neurological decline in GD3, potentially transforming the outlook for patients who until now had no treatment options for this aspect of their disease. Ongoing research and monitoring will clarify the long-term impact, safety, and accessibility of Infilbray as its global rollout proceeds.